Lupus

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wierzbicki, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wierzbicki, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Lupus, Vol. 9, No. 3, 194-201 (2000)
DOI: 10.1191/096120300678828235

Reviews

Lipids, cardiovascular disease and atherosclerosis in systemic lupus erythematosus

As Wierzbicki

Department of Chemical Pathology, Guy's, King's and St. Thomas' Medical School (King's College London), St. Thomas' Hospital Campus, London, UK; Department of Chemical Pathology, St. Thomas' Hospital, Lambeth Palace Road, London SEl 7EH, UK Tel: (44)17l 928 9292X2027; Fax: (44)17l 928 4226; anthony.wierzbicki{at}kcl.ac.uk

Systemic lupus erythematosus is commonly associated with early onset cardiovascular disease and is often associated with hyperlipidaemia. This review examines the evidence for an increased prevalence of both CHD and hyperlipidaemia in SLE and mechanisms by which autoimmunity in SLE could accelerate the progression of atheroma. It postulates how lipid lowering therapies used in cardiological disease might help reduce the incidence of CHD in SLE.

Key Words: systemic lupus erythematosus • atherosclerosis • cardiovascular disease • lipids • apolipoproteins


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 LupusHome page
A. Negron, M. Molina, A. Mayor, V. Rodriguez, and L. Vila
Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico
Lupus, April 1, 2008; 17(4): 348 - 354.
[Abstract] [PDF]

Home page
 Rheumatology (Oxford)Home page
T. K. Tso, W.-N. Huang, H.-Y. Huang, and C.-K. Chang
Relationship of plasma interleukin-18 concentrations to traditional and non-traditional cardiovascular risk factors in patients with systemic lupus erythematosus
Rheumatology, September 1, 2006; 45(9): 1148 - 1153.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
N Espinola-Zavaleta, E Alexanderson-Rosas, N Granados, M E. Soto, and M-C Amigo
Myocardial perfusion defects in patients with autoimmune diseases: a prospective study. Analysis of two diagnostic tests
Lupus, January 1, 2006; 15(1): 38 - 43.
[Abstract] [PDF]

Home page
 Rheumatology (Oxford)Home page
S. L. Nuttall, S. Heaton, M. K. Piper, U. Martin, and C. Gordon
Cardiovascular risk in systemic lupus erythematosus--evidence of increased oxidative stress and dyslipidaemia
Rheumatology, June 1, 2003; 42(6): 758 - 762.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
F Formiga, J F Meco, X Pinto, J Jacob, I Moga, and R Pujol
Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients
Lupus, May 1, 2001; 10(5): 359 - 363.
[Abstract] [PDF]

Home page
 LupusHome page
A S Wierzbicki
Lipid-lowering drugs in lupus: an unexplored therapeutic intervention
Lupus, March 1, 2001; 10(3): 233 - 236.
[Abstract] [PDF]